Dr. Denlinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-7526
Education & Training
Ohio State University HospitalResidency, Internal Medicine, 2015 - 2018
Ohio University Heritage College of Osteopathic Medicine in AthensClass of 2015
Certifications & Licensure
OH State License 2015 - 2025- American Board of Internal Medicine Internal Medicine
Clinical Trials
- DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Roles: Contact
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Start of enrollment: 2024 Jan 29
Roles: Sponsor-Investigator
Publications & Presentations
PubMed
- 37 citationsComorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam Kittai, Ying Huang, Max J. Gordon, Nathan Denlinger, Agrima Mian
Transplantation and Cellular Therapy. 2021-01-01 - 41 citationsAllogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo
Haematologica. 2023-01-01 - 32 citationsCAR T-cell therapy for B-cell lymphoma.Nathan Denlinger, David Bond, Samantha Jaglowski
Current Problems in Cancer. 2022-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
